Inactive Instrument

Other languages Foamix Pharmaceuticals Ltd. Nasdaq

Equities

IL0011334385

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	Jan. 10
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	Jan. 03
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	23-10-30
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	23-10-30
Top Premarket Gainers	23-10-30
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	23-10-30
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
VYNE Therapeutics Inc. Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions	23-05-01
VYNE Therapeutics Inc. Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis	23-04-19
Sector Update: Healthcare Stocks Mostly Higher Late Thursday	23-03-30
Sector Update: Health Care Stocks Mixed Thursday Afternoon	23-03-30
Sector Update: Health Care	23-03-30
Vyne Therapeutics Says Vitiligo Drug Candidate Has No Negative Effect on Platelet Count in Phase 1a Trial; Shares Rise	23-03-30
VYNE Therapeutics Inc. Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1A Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain Bet Inhibitor Vyn201	23-03-30
VYNE Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	23-03-13
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Foamix Pharmaceuticals Ltd. Nasdaq

Equities

IL0011334385

Other languages

Filters